15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Karyopharm Therapeutics Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $13.00 to $28.00 (about 2.2x), a sign of real disagreement on valuation. The average target of $18.20 sits 157% above the current $7.07. The rating mix has stayed broadly stable, with Buy-side ratings easing from 7 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.21 next quarter toward $-4.89 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Karyopharm Therapeutics Inc.
As of Jul, 6 of 6 firms rate KPTI a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
KPTI EPS & revenue forecast
EPS · NEXT QUARTER
$-1.21
Range $-1.61 – $-0.81 · 3 analysts · -68% YoY
Next period, 3 analysts expect Karyopharm Therapeutics Inc to earn $-1.21 a share (range $-1.61 – $-0.81), versus $-3.82 a year earlier. Full-year consensus is $-4.95, growing to $-4.89 the year after.
REVENUE · NEXT QUARTER
$34.2M
Range $29.9M – $39.8M · 3 analysts · -22% YoY
Revenue is expected to reach $34.2M (range $29.9M – $39.8M), -22.3% year-over-year. Full-year consensus is $138.2M, rising to $149.0M next year.
Top analysts covering Karyopharm Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KPTI.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$13.00+83.9% to target
Overall win rate
38%
+ Follow
#2
EW
Edward White
HC Wainwright & Co. · Rank #241
Buy
$56.00+692.1% to target
Overall win rate
31%
+ Follow
#3
Edward Tenthoff
Piper Sandler · Rank #277
Buy
$16.00+126.3% to target
Overall win rate
29%
+ Follow
#4
Brian Abrahams
RBC Capital · Rank #311
Buy
$19.00+168.7% to target
Overall win rate
25%
+ Follow
#5
MU
Michael Ulz
Baird
Buy
$15.00+112.2% to target
Coverage
—
+ Follow
KPTI stock forecast FAQ
What is KPTI's average 12-month price target?+
The 5 analysts with a live target average $18.20 for Karyopharm Therapeutics Inc over the next 12 months, ranging from a $28.00 high to a $13.00 low.
Is KPTI stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for KPTI?+
The Street-high target is $28.00 (Rodman & Renshaw), and the Street-low is $13.00 (HC Wainwright & Co.). The average of all 5 active targets is $18.20.
How many Wall Street analysts cover KPTI?+
6 analysts have an active rating on Karyopharm Therapeutics Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering KPTI?+
Among analysts who currently cover KPTI, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #195). Their current call is Buy with a $13.00 target.
What is Karyopharm Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.21 per share (range $-1.61 – $-0.81) across 3 analysts. Full-year EPS is projected at $-4.95, rising to $-4.89 the following year.
How much revenue is Karyopharm Therapeutics Inc expected to report next quarter?+
Consensus revenue is $34.2M (range $29.9M – $39.8M). Full-year revenue is projected at $138.2M, growing to $149.0M next year.
Have analysts been upgrading or downgrading KPTI lately?+
As of Jul, 6 of 6 firms rate KPTI a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KPTI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
